Tilray Brands (NASDAQ:TLRY) Trading Down 6.8% – Time to Sell?

Tilray Brands, Inc. (NASDAQ:TLRY)’s stock price was down 6.8% on Friday . The stock traded as low as $6.15 and last traded at $6.21. Approximately 3,480,644 shares were traded during trading, a decline of 8% from the average daily volume of 3,775,012 shares. The stock had previously closed at $6.66.

Tilray Brands News Roundup

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray Medical announced its largest medical-cannabis portfolio expansion in Australia, reinforcing patient access and signaling commitment to a growth market — a revenue and patient-share catalyst for TLRY’s medical segment. Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia
• Positive Sentiment: Tilray Medical, CC Pharma and 14U Pharma formed a strategic alliance with “gesund leben” and Alliance Healthcare Deutschland to accelerate market expansion in Germany — a distribution and commercialization boost for EU sales. Tilray Medical, CC Pharma, and 14U Pharma Announce Strategic Alliance
• Positive Sentiment: CEO Irwin Simon told Just Drinks the company is focused on “putting stability in place” for BrewDog — signaling management attention on operational turnaround and margin stabilization in its beverage segment. “We need to put stability in place” – Tilray Brands CEO on what lies ahead for BrewDog
• Neutral Sentiment: Market write-ups note TLRY is slipping more than the broader market in recent sessions—useful short-term context but largely descriptive of current flow rather than new fundamental news. Tilray Brands, Inc. (TLRY) Dips More Than Broader Market: What You Should Know
• Negative Sentiment: Technical analysts warn TLRY has lost a key support level and suggest downside toward ~$5 is possible if selling continues — a short-term bearish signal that can amplify downside as stops trigger. Tilray stock price has just lost a key support: is a crash to $5 coming?

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on TLRY shares. ATB Cormark Capital Markets upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 10th. Canaccord Genuity Group assumed coverage on shares of Tilray Brands in a research note on Tuesday, January 27th. They issued a “hold” rating for the company. Wall Street Zen downgraded Tilray Brands from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. Finally, Zacks Research raised Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.33.

Tilray Brands Stock Performance

The stock has a market capitalization of $722.36 million, a price-to-earnings ratio of -0.28 and a beta of 1.96. The stock’s 50-day simple moving average is $7.89 and its 200 day simple moving average is $10.59. The company has a quick ratio of 1.72, a current ratio of 2.81 and a debt-to-equity ratio of 0.19.

Tilray Brands (NASDAQ:TLRY) last released its quarterly earnings results on Thursday, January 8th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.12. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.The firm had revenue of $217.51 million during the quarter, compared to analysts’ expectations of $211.15 million. During the same period last year, the firm posted ($0.03) EPS. Analysts expect that Tilray Brands, Inc. will post -0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tilray Brands

Hedge funds and other institutional investors have recently made changes to their positions in the company. Silverlake Wealth Management LLC acquired a new stake in shares of Tilray Brands during the 3rd quarter worth approximately $25,000. Oppenheimer & Co. Inc. acquired a new stake in Tilray Brands during the 3rd quarter worth approximately $25,000. Unified Investment Management acquired a new stake in shares of Tilray Brands during the third quarter worth $26,000. J.W. Cole Advisors Inc. raised its stake in shares of Tilray Brands by 203.2% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company’s stock valued at $30,000 after purchasing an additional 48,177 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Tilray Brands in the 3rd quarter valued at approximately $30,000. 9.35% of the stock is owned by institutional investors and hedge funds.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.